Glutamine Suppletion Minimizes the Atrial Fibrillation Burden

Glutamine Suppletion Minimizes the Atrial Fibrillation Burden - Glutaminimize AF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON46467

Enrollment

Registered

2018-01-31

Start date

2018-05-02

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Oral intake of L-glutamine supplement (KABI Glutamine, 20 gr sachets of which 10 gr L-glutamine, twice daily)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult (>18 years), frequent (>1/week) symptomatic atrial fibrillation

Exclusion criteria

Exclusion criteria: Diabetes mellitus, soya, gluten or shell fish allergy

Design outcomes

Primary

Measure	Time frame
Primary study parameters are the HSP levels of HSP27 and HSP70 in blood at baseline, after 3 months and after 6 months. Main endpoint is completion of 6 months follow-up period.	—

Secondary

Measure	Time frame
Secondary study parameters are the AF incidence and burden at baseline, after 3 months and after 6 months. Furthermore the correlation between the HSP levels and the AF incidence and burden will be derived at baseline, after 3 months and after 6 months.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)